Company: RGBP
Filing Date: 2025-12-05
Form Type: 253G1
Source: 0001493152-25-026350
Chunk: 65

Company: Regen BioPharma Inc
Filing Date: 2025-12-05
Form: 253G1
Chunk 65
---
,338 |     | $      | 3 |     | $                  | 15,504,134 |   |     | $                   | (204,847 | ) |     | $           | (21,119,151 | ) |     | $     | (5,815,691 | ) |

<div align='center'>The accompanying notes are an integral part of the consolidated financial statements.

48

REGEN BIOPHARMA, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(unaudited)</div>

|                                               |     | Three Months ended June 30, 
 2025                        |          |   |     | 2024 |          |   |     | Nine Months ended June 30, 
 2025                       |          |   |     | 2024 |          |   |
|:----------------------------------------------|:----|:----------------------------|:---------|:--|:----|:-----|:---------|:--|:----|:---------------------------|:---------|:--|:----|:-----|:---------|:--|
| Net loss                                      |     | $                           | (167,292 | ) |     | $    | (130,120 | ) |     | $                          | (702,033 | ) |     | $    | (397,507 | ) |
| Other comprehensive income, net of tax        |     |                             |          |   |     |      |          |   |     |                            |          |   |     |      |          |   |
| Net unrealized gains on investment securities |     |                             | -        |   |     |      | -        |   |     |                            | -        |   |     |      | (204,847 | ) |
| Other comprehensive income, net of tax        |     |                             | -        |   |     |      | -        |   |     |                            | -        |   |     |      | (204,847 | ) |
| Comprehensive loss                            |     | $                           | (167,292 | ) |     | $    | (130,120 | ) |     | $                          | (702,033 | ) |     | $    | (602,354 | ) |

<div align='center'>The accompanying notes are an integral part of the consolidated financial statements.

49

REGEN BIOPHARMA, INC.